ClinVar Miner

Submissions for variant NM_000767.5(CYP2B6):c.785A>G (p.Lys262Arg) (rs2279343)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
DNA and Cytogenetics Diagnostics Unit,Erasmus Medical Center RCV000106294 SCV000745387 benign Efavirenz response 2015-08-05 criteria provided, single submitter clinical testing
Diagnostic Laboratory, Department of Genetics,University Medical Center Groningen RCV000106294 SCV000733894 benign Efavirenz response no assertion criteria provided clinical testing
OMIM RCV000106294 SCV000143753 drug response Efavirenz response 2015-05-15 no assertion criteria provided literature only
PharmGKB RCV000211381 SCV000268261 drug response efavirenz response - Metabolism/PK 2016-03-22 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.